Genevant Sciences
Biotechnology ResearchBritish Columbia, Canada51-200 Employees
Genevant Sciences is a biotechnology research company based in Vancouver, British Columbia, focused on delivering nucleic acid therapies via lipid nanoparticle platforms. It maintains a broad patent portfolio and decades of nucleic acid drug development experience, enabling collaborations with leading pharma and biotech firms, and it contributed to the development of the first and only FDA-approved siRNA-LNP that uses Genevant technology. The company's approach centers on enabling partners to bring RNA medicines and gene-editing therapeutics to patients through its delivery technologies. Its LNP platform has been evaluated in more than a dozen clinical programs, involving hundreds of subjects and patients. In 2024, Genevant entered into a collaboration with Editas Medicine to develop novel mRNA-LNP gene-editing therapeutics, illustrating the breadth of its applications. Genevant positions itself as a leader in delivery, expanding beyond liver targeting to other tissues and cell types.
1-888-653-2347 
support@leadiq.com 
